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Purpose: The goal of this study was to review published literature regarding the impact of preoperative
diabetes mellitus (DM) in patients undergoing pancreatectomy.
Methods: Ovid Medline of a biomedical database was used on subjective literature research.
Results: The prevalence of preoperative DM was 30.9e54.9% in patients with pancreatic cancer and was
5.3e10.8% in patients with chronic pancreatitis. There were few reports that described the relationship
between preoperative DM status and postoperative morbidity/mortality, or long-term survival after
pancreatectomy. The incidence of pancreatic ﬁstula of Grade B and C [deﬁned by International Study
Group on Pancreatic Fistula Deﬁnition (ISGPF)] was similar when comparing patients with and without
preoperative DM. Furthermore, the incidence of death and various morbidities (e.g., infections, cardio-
vascular complications, clinically signiﬁcant level of acute renal failure after pancreatectomy, and delayed
gastric emptying after pancreaticoduodenectomy) were not signiﬁcantly different when comparing
patients with and without preoperative DM. It is unclear whether preoperative DM has an impact on
long-term survival after pancreatectomy, and the difﬁculty in assessing this parameter may be due to
different deﬁnitions of DM, different surgical methods, and different comorbidities when comparing
different studies.
Conclusions: The occurrence rates of postoperative mortality and morbidities including pancreatic ﬁstula
and renal failure of moderate to severe degrees were almost same between patients with and without
preoperative DM. The inﬂuence of preoperative DM on long term survival after pancreatectomy should
be elucidated by future studies under accurate and consistent deﬁnitions of DM.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Diabetes mellitus (DM) can be classiﬁed into four different types
according to the American Diabetes Association (ADA)1: type 1
diabetes, type 2 diabetes, gestational diabetes, and other speciﬁc
types of diabetes (type 3). The cause of type 1 diabetes is destruc-
tion of insulin-producing b-cells in the pancreatic islets of Langer-
hans, mainly by T-cell-mediated autoimmune attack, resulting in
insulin deﬁciency. Type 1 diabetes accounts for 5e10% of all cases of
DM and commonly occurs with juvenile onset and is usually
responsive to treatment with exogenous insulins. Type 2 diabetes is
a lifestyle (e.g., excess calorie intake and physical inactivity)-related
disease and accounts for 90e95% of cases of DM. The cause of type 2
diabetes is a defect in the responsiveness of body tissues to insulin: þ81 72 970 2120.
ata).
ciates Ltd. Published by Elsevier Ltas a result of unknown mechanisms. Gestational diabetes occurs in
2%e5% of all pregnancies and resembles type 2 diabetes, except
that it typically improves or resolves after delivery. The “other
speciﬁc type” category can be subclassiﬁed into eight pathophysi-
ological entities (coded from “A” to “H”) according to the ADA,
and one of those entities is ‘disease of the exocrine pancreas’
(coded as “C”), which includes pancreatitis, trauma/pancreatec-
tomy, neoplasm, and cystic ﬁbrosis. This entity is generally called
“pancreatogenic diabetes” and is also called “type 3C DM” in the
ADA classiﬁcation.
Long-term duration of hyperglycemia in patients with uncon-
trolled DM leads to heart disease, stroke, foot ulcers, renal failure,
retinopathy, and neuropathy via a complex and multifactorial
pathophysiology, including atherosclerosis, impaired autor-
egulation of blood ﬂow, inﬂammatory response, oxidative stress,
and a hypercoagulable state.2 Therefore, it is possible that patients
with preoperative DM have higher morbidity and mortality after
surgery when compared to those without DM. This review articled. All rights reserved.
Table 2
Indication for pancreatectomy.
Disease Kind of pancreatectomy
Pancreatic cancer PD, DP, TP
Middle and distal bile duct cancer PD
Ampullary cancer PD
Duodenal cancer PD
Pancreatic neuroendocrine tumor PD, DP, TP, CP, EN
Intraductal papillary mucinous tumor PD, DP, TP
Mucinous cystic tumor PD, DP, CP
Serous cystadenocarcinoma PD, DP, CP
Solid-pseudopapillary tumor PD, DP, TP, CP, EN
Chronic pancreatitis PD, DP, TP
Trauma to the pancreas PD, DP, TP, CP
Kind of pancreatectomy was the most frequently selected operation method ac-
cording to the location and extent of disease.
PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatec-
tomy; CP, central pancreatectomy; EN, enucleation.
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tions and outcomes after pancreatectomy in patients with preop-
erative DM. Pancreatogenic diabetes caused by pancreatectomy, or
deterioration of glucose tolerance post-pancreatic resection is not
dealt with in this review article; that subject is covered in other
reviews and original articles.3e11
2. Methods
2.1. Literature search
A literature search was conducted through Ovid Medline 1946 to Present with
Daily & Weekly Update using the keywords diabetes mellitus ‘AND’ pancreatectomy
‘OR’ pancreaticoduodenectomy. Literature surveys were also on the same biomed-
ical database using keywords diabetes mellitus ‘AND’ pancreatic cancer ‘OR’ bile
duct cancer ‘OR’ ampullary cancer ‘OR’ duodenal cancer ‘OR’ pancreatic neuroen-
docrine tumor ‘OR’ glucagonoma ‘OR’ somatostatinoma ‘OR’ intraductal papillary
mucinous tumor ‘OR’ mucinous cystic tumor ‘OR’ serous cystadenocarcinoma ‘OR’
solid-pseudopapillary tumor ‘OR’ chronic pancreatitis.
2.2. Deﬁnition of DM
The ADA has issued comprehensive diagnostic criteria for DM.1 For patients with
classic symptoms of hyperglycemia or with hyperglycemic crisis, a random plasma
glucose level of 200 mg/dl is sufﬁcient for the diagnosis of DM. For patients
without unequivocal hyperglycemia, criteria (1)e(3) should be conﬁrmed on more
than one occasion: (1) hemoglobin A1c (HbA1c) 6.5%; (2) fasting plasma glucose
126mg/dl after fasting for at least 8 h; or (3) 2-h value of plasma glucose200mg/
dl during an oral glucose tolerance test. However, the deﬁnitions of DM in the
published literature do not always follow these ADA criteria. Various organizations
aside from the ADA (e.g., World Health Organization, International Diabetes Feder-
ation, European Association for the Study of Diabetes, Canadian Diabetes Associa-
tion, and the Japan Diabetes Society) have issued their own diagnostic guidelines for
DM that may differ from those of the ADA. Therefore, caution is required when
comparing results between studies that have used different diagnostic criteria for
DM (Table 1).
3. Results
3.1. Prevalence of preoperative DM in patients undergoing
pancreatectomy
Table 2 summarizes various diseases that may serve as an
indication for pancreatectomy. There are few studies that describeTable 1
Prevalence and deﬁnition of preoperative diabetes mellitus in patients undergoing panc
Authors Disease Pancreatectomy Rate of p
diabetic
total pat
Sperti et al. Pancreatic cancer PD (68.1%), DP (20.4%), TP (11.5%) 54.9%
Chu et al. Pancreatic cancer PD (87.6%), DP (11.6%), TP (0.8%) 46.2%
Chagpar et al. Pancreatic cancer Not itemized 30.9%
Dandona et al. Pancreatic cancer PD (100%) 32.7%
White et al. Pancreatic cancer PD (78.2%), DP (20.8%), TP (1.0%) 41.6%
Cannon et al. Pancreatic cancer PD (86.8%), DP (11.2%), STP (1.4%),
CP (0.2%)
31.2%
Jalleh et al. Chronic pancreatitis PD (100%) 5.3%
Berney et al. Chronic pancreatitis PD (51.5%), DP (45.6%), TP (2.9%) 8.8%
Hutchins et al. Chronic pancreatitis DP (100%) 10.8%
PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy; STP
OGTT, oral glucose tolerance test.
Percentage for each category of pancreatectomy is relative to the total number of operathe prevalence of preoperative DM in patients with diseases
(Table 2), with the exception of pancreatic cancer and chronic
pancreatitis (Table 1). Rather, most studies describe the prevalence
of DM among a combined cohort of patients with resectable and
unresectable pancreatic pathology, and even those types of data are
very limited. A Japanese multi-institutional study demonstrated
that 19.1% (264/1379) of patients with intraductal papillary
mucinous tumor (IPMT) and 12.9% (23/179) of patients with
mucinous cystic tumor (MCT) had DM among patients with either
resectable or unresectable pancreatic disease.12 The prevalence of
DM was higher in IPMT or MCT patients than in healthy controls,
which has been reported to be 7%.13 DM associated with pancreatic
cancer, chronic pancreatitis, IPMT, or MCT is etiologically classiﬁed
as type 3C according to ADA criteria when these tumors are
responsible for the occurrence of DM. Association of pancreatic
cancer with DM has been well investigated and is summarized in
the next section of this review article. Two types of very rare islet
cell tumors (i.e., glucagonoma and somatostatinoma) are associated
with DM via hormonal mechanisms and are categorized as ‘endo-
crinopathies’ of the “other speciﬁc type” category (type 3D), ac-
cording to the ADA criteria. Glucagonoma secretes glucagon, whichreatectomy for pancreatic cancer and chronic pancreatitis.
reoperative
patients to
ients
Number
of total
patients
Deﬁnition of diabetes mellitus
in the literature
Published
year
[reference]
113 Not deﬁned in the manuscript 199618
251 Diabetic history and/or FPG 126 mg/dL
and/or random plasma glucose
200 mg/dL (repeatedly)
201019
515 Diabetic history and/or outpatient FPG
>126 mg/dL, random plasma glucose
200 mg/dL, or inpatient plasma glucose
200 mg/dL prior to 7 am on 2 days
201120
355 Diabetic history 201121
101 Diabetic history and/or FPG >126 mg/dL
and/or random plasma glucose
>200 mg/dL (two times)
201122
509 Diabetic history and/or FPG 126 mg/dL
and/or random plasma glucose
200 mg/dL (repeatedly)
201223
38 FPG >120 mg/dL and/or 2-h value of
plasma glucose >180 mg/dL during OGTT
19923
68 Diabetic history 20004
74 FPG >120 mg/dL and/or 2-h value of
plasma glucose >180 mg/dL during OGTT
20026
, subtotal pancreatectomy; CP, central pancreatectomy; FPG, fasting plasma glucose;
tions.
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produce somatostatin, which suppresses both insulin and glucagon
production, resulting inmild DM. There are approximately 200 case
reports each of these tumors in the English literature. The majority
of patients with glucagonoma (76.2e94%)14,15 or somatostatinoma
(65.2e77.8%)16,17 have DM at the time of diagnosis.
3.2. Pancreatic cancer and DM
As shown in Table 1, approximately one-third to one-half of
patients with pancreatic cancer who undergo pancreatectomy
have preoperative DM.18e23 Several studies have described the
associations between DM (type 1 or type 2) and pancreatic can-
cer,24,25 but nearly all of these studies used an inaccurate deﬁnition
of DM (e.g., self-reported diagnosis, or history of taking an anti-
diabetic agent without objective ﬁndings of DM). A recent meta-
analysis of caseecontrol and cohort studies reported that the
odds ratio of type 2 DM for patients with pancreatic cancer was
1.82.24 The same meta-analysis found that patients with long-
standing DM (history of >5 years) had a 50% higher relative risk
for pancreatic cancer when compared with subjects without DM.
Furthermore, patients who suffered from DM for 4 years or less
had a 50% greater risk of pancreatic cancer when compared to
those with long-standing DM.24 The majority of DM cases associ-
ated with pancreatic cancer are new-onset; 75e88% of patients
with pancreatic cancer and DM had a duration of DM less than 2
years.13,26 Therefore, subjects with new-onset DM should be
evaluated for underlying pancreatic cancer, especially those who
do not have conventional risk factors (e.g., obesity, family history of
DM) for type 2 DM.27 However, screening for pancreatic cancer in
all patients with new-onset DM is not cost-effective, because the
prevalence of pancreatic cancer in patients with new-onset DM is
less than 1%.28,29 Consequently, investigators have tried to estab-
lish biomarkers that could discriminate between pancreatic
cancer-associated DM and type 2 DM.30,31 Exacerbation of preex-
isting DM has also been recognized as an early manifestation of
pancreatic cancer. Interestingly, several studies have demonstrated
that new-onset DM complicated by pancreatic cancer subse-
quently improves after pancreatectomy.13,32e34 These ﬁndings
support the notion that tumor-secreted products may induce DM
associated with pancreatic cancer.
Some studies have reported that DM medication or DM status
(e.g., hyperinsulinemia and insulin resistance) may be carcinogenic
for the pancreas.35,36 For example, sulfonylurea and insulin have
been recognized as risk factors of pancreatic cancer,37e39 while
metformin, a biguanide, has been shown to reduce the risk of
pancreatic cancer.38 Metformin decreases hepatic gluconeogenesis,
acts as a peripheral insulin sensitizer, and decreases the plasmaTable 3
Postoperative morbidity and survival in DM and non-DM patients undergoing pancreate
Authors Disease Pancreatectomy Pt. no. of DM vs.
non-DM
Srivastava et al. Pancreatic and
periampullar tumor
PD 25 vs. 95
DeOliveira et al. Malignant and
benign diseases
PD Total 633
(not itemized)
Sperti et al. Pancreatic cancer PD, DP, TP 62 vs. 51
Chu et al. Pancreatic cancer PD, DP, TP 116 vs. 135
Chagpar et al. Pancreatic cancer Not itemized 159 vs. 356
Dandona et al. Pancreatic cancer PD 116 vs. 237
Cannon et al. Pancreatic cancer PD, DP, STP, CP 78 vs. 167
Pt., patient; DM, diabetes mellitus; PD, pancreaticoduodenectomy; DP, distal pancreatec
atectomy; R, related to DM status; NR, not related to DM status; *, not assessed.
Deﬁnitions of pancreatic ﬁstula varied between the individual investigations; see text.
Delayed gastric emptying, deﬁned by the International Study Group of Pancreatic Surgeinsulin level, thereby blocking the proliferative effects of insulin on
cancer cells. Additionally, metformin has a direct antineoplastic
effect via blockade of phosphatidylinositol 3-kinase/Akt/mTOR
signaling pathways.38
3.3. Postoperative outcomes after pancreatectomy in patients with
preoperative DM
There are relatively few reports on the impact of preoperative
DM on perioperative complications or survival after pancreatec-
tomy. Table 3 is a summary of the literature regarding this subject.
3.3.1. Pancreatic ﬁstula
Postoperative pancreatic ﬁstula is the most frequent major
complication associated with prolonged hospital stay, and this
complication can lead to life-threatening events, such as sepsis and
organ dysfunction. To allow direct comparison of endpoints be-
tween surgical institutions, the International Study Group on
Pancreatic Fistula Deﬁnition (ISGPF)40 published their deﬁnition of
postoperative pancreatic ﬁstula in 2005 as drain output of any
measurable volume of ﬂuid on or after postoperative day 3 with
elevated amylase content (>3 times the normal level of serum
amylase). Three different grades (fromA to C) are deﬁned according
to the clinical impact of the ﬁstula on the patient’s hospital course.
Grade A is the most common type of ﬁstula and is transient in
nature. Patients with Grade A ﬁstula are in good clinical condition
and require no speciﬁc treatment. Grade C is the worst type of
ﬁstula, and this phenomenon requires institution of speciﬁc treat-
ments, including: cessation of oral intake; institution of total
parental nutrition, intravenous antibiotics, and somatostatin ana-
logues; drainage; and sometimes reoperation. While the deﬁnition
of the ISGPF has been generally adopted for the evaluation of
pancreatic ﬁstula, one should note that deﬁnitions can still vary
between studies, particularly in studies that were performed prior
to 2005.
In 2001, Srivastava et al. used multivariate logistic regression
analysis to identify risk factors for pancreaticoenteric anastomosis
(PEA) leak in 120 patients with pancreatic and periampullary tu-
mors who underwent pancreaticoduodenectomy (PD). Their deﬁ-
nition of PEA leak was: drainage of >10 mL of ﬂuid with elevated
amylase content (>3 times the normal level of serum amylase) for 4
days; percutaneous drainage of amylase-rich intra-abdominal
collection/abscess; or intraoperative demonstration of PEA
disruption. Therefore, their cases of PEA leak paralleled the de-
scriptions of the Grade A to C classiﬁcation of the ISGPF. They
concluded that patients with preoperative DM showed a signiﬁ-
cantly higher incidence of PEA leak than those without DM (28% vs.
8.4%, respectively; P < 0.05).41 In 2006, DeOliveira et al. publishedctomy.
Pancreatic
ﬁstula
Delayed gastric
emptying
Postoperative
mortality
Survival Published year
[reference]
R * * * 200141
NR NR * * 200642
* * * R 199618
R NR NR * 201019
* * NR * 201120
* * * NR 201121
* * * R 201223
tomy; TP, total pancreatectomy; STP, subtotal pancreatectomy; CP, central pancre-
ry.43
B. Nakata et al. / International Journal of Surgery 11 (2013) 757e761760
REVIEWdata regarding complications after PD from 633 patients with
various benign and malignant diseases. Their deﬁnition of
pancreatic ﬁstula was persistent drainage of 50 mL with elevated
amylase content (>3 times the normal level of serum amylase) on
or after postoperative day 10, or pancreatic anastomotic disruption
that was demonstrated radiologically. According to that deﬁnition,
a substantial portion of patients with ISGPF Grade A ﬁstula may be
classiﬁed into the “no pancreatic ﬁstula” group in their series. By
multivariate logistic regression analysis of their examined risk
factors, preoperative DM was not a signiﬁcant indicator for devel-
oping pancreatic ﬁstula.42 Chu et al. compared postoperative
morbidities and mortalities after pancreatectomy between a pre-
operative DM group and a non-DM group in 251 patients with
histologically proven pancreatic cancer.19 A signiﬁcantly higher rate
of pancreatic ﬁstula, including those of Grade AeC as deﬁned by the
ISGPF, occurred in the DM group than in the non-DM group (10.3%
vs. 3.7%, respectively; P ¼ 0.04). Moreover, logistic regression
analysis revealed that preoperative DM was independent of the
occurrence of pancreatic ﬁstula (odds ratio, 4.31; 95% conﬁdence
interval [CI], 1.18e15.77; P ¼ 0.027). However, with regard to clin-
ically signiﬁcant ﬁstula (i.e., ISGPF grade B or C), there were no
signiﬁcant differences between the two groups (DM group, 5.2% vs.
non-DM group, 4.4%). These observations suggest that patients
with preoperative DM may have a higher risk of any type of
pancreatic ﬁstula than those without DM. However, the risk of
ISGPS grade B and C ﬁstulas may be similar when comparing pa-
tients with preoperative DM and those without DM.
3.3.2. Delayed gastric emptying and other complications
A higher rate of delayed gastric emptying (DGE) would be ex-
pected in patients with preoperative DMwho undergo PD, because
DM is the most common cause of gastroparesis. However, previous
clinical observations have not shown any association between
preoperative DM status and DGE after PD. For example, DeOliveira
et al. showed that there was no relationship between preoperative
DM status and DGE at Johns Hopkins Hospital in patients who
underwent PD for one of various diseases.42 Chu et al. also
demonstrated that there was no signiﬁcant difference in the inci-
dence of DGE [as deﬁned by International Study Group of Pancre-
atic Surgery (ISGPS)]43 when comparing DM and non-DM groups
among 220 patients who underwent PD.19 In brief, DGEwas deﬁned
by the ISGPS as the inability to return to a standard diet by the end
of the ﬁrst postoperative week and includes the need for prolonged
nasogastric intubation. Chu et al. also demonstrated that the rates
of infections (38.8% vs. 38.5%, respectively), and cardiovascular
(10.3% vs. 6.7%, respectively) and respiratory complications (19.0%
vs. 14.1%, respectively) in DM and non-DM groups were similar
among 251 patients who underwent pancreatectomy, including PD,
distal pancreatectomy, and total pancreatectomy. In the Chu’s series
of patients, the DM group had a signiﬁcantly higher rate of acute
renal failure (including asymptomatic renal failure or a minor rise
in serum creatinine level above baseline) than the non-DM group
(23.3% vs. 12.6%, respectively; P ¼ 0.03). However, the rate of clin-
ically signiﬁcant acute renal failure with oliguria requiring renal
replacement therapy was similar when comparing the two groups
(1.7% vs. 1.5%, respectively).19
3.3.3. Postoperative mortality and long-term survival after
pancreatectomy
Chu et al. showed that the perioperativemortality ratewithin 60
days after resection of pancreatic cancer in preoperatively diabetic
patients was not signiﬁcantly greater than that in non-diabetic
patients, as analyzed by the chi-squared test (4.3% vs. 3.0%).19
Chagpar et al. investigated a multi-institutional database of 515
patients with pancreatic cancer who underwent pancreatectomy.They reported that the prevalence of preoperative DM between
patients who died within 90 days and those who survived for more
than 90 days postoperatively was not signiﬁcantly different, ac-
cording to univariate analysis [44.8% (13/29) vs. 30.0% (146 of 486),
respectively; P ¼ 0.101].20
With regard to long-term survival after pancreatectomy, Sperti
et al. analyzed 113 patients with pancreatic cancer and demon-
strated that the median survival time of patients with preoperative
DM was signiﬁcantly shorter than that of patients without preop-
erative DM (13 months vs. 24 months; P ¼ 0.001), according to
univariate survival analysis.18 Their multivariate survival analysis
demonstrated that preoperative DM was a signiﬁcant independent
determinant of long-term survival (P ¼ 0.003). Cannon et al. found
that preoperative DM was associated with both overall survival
(OS) and disease-free survival (DFS) by univariate and multivariate
survival analysis among 245 patients with pancreatic cancer who
underwent pancreatectomy. The OS and DFS hazard ratios for
preoperative DM were 1.99 (95% CI, 1.40e2.82; P < 0.001) and 1.67
(95% CI, 1.32e2.11; P < 0.001), respectively, according to multivar-
iate survival analysis.23 In contrast, Dandona et al. reported that
preoperative DM did not inﬂuence OS, as analyzed by a univariate
Cox proportional hazard model among 353 patients with pancre-
atic cancer who underwent PD in a multicenter study (hazard ratio,
0.87; 95% CI, 0.66e1.14; P ¼ 0.31).21 It is not clear why the result of
Dandona was different from those of Sperti and Cannon, but the
contradictory results may be attributed to differences in surgical
methods, deﬁnitions of DM, and statistical methods used among
these studies. For example, the patients in Sperti’s and Cannon’s
series underwent various pancreatectomy procedures, including
PD and DP, among others, while those in Dandona’s series were
limited to PD. The deﬁnition of DM for Sperti’s series was not
described in their manuscript. The patients in Dandona’s series
were deﬁned as DM according to diabetic history through self
report, whereas diagnoses in Cannon’s series were achieved via
both diabetic history and biochemical investigation (Table 1).4. Conclusion
Investigations of operative morbidity and survival in patients
with preoperative DM who underwent pancreatectomy are rare.
Moreover, the deﬁnitions of DM in the limited number of studies
varied, making it difﬁcult to compare data between studies.
To summarize the results from previous reports, the occurrence
rates of moderate to severe morbidities, such as ISGPF Grade B or C
pancreatic ﬁstula or acute renal failure requiring renal replacement
therapy, were similar among patients with and without preopera-
tive DM, suggesting that there is no signiﬁcant difference in the rate
of postoperative mortalities between the two groups. The impact of
preoperative DM on long-term survival after pancreatectomy re-
mains controversial. Further studies using accurate and consistent
deﬁnitions of DM are required.
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